

Strengthening of the Tecan Group Executive Committee: Heads appointed for the two new business segments

- **Frederic Vanderhaegen to be Head of the new Life Sciences Business Segment**
- **Bernhard Grob to be Head of the new Partnering Business Segment**
- **Matthew Robin, formerly Head of Liquid Handling & Robotics, to leave Tecan**

Männedorf, Switzerland, November 9, 2010 – The Board of Directors of the Tecan Group (SIX Swiss Exchange: TECN) has confirmed the appointments of the heads of the two new business segments Life Sciences Business and Partnering Business. The new organization will come into effect on January 1, 2011.

Frederic Vanderhaegen, previously Head of Business Unit Detection, will take over the Life Sciences Business (end-customer business). He has been with Tecan since 2008 and is already a member of the Group Executive Committee. Prior to joining Tecan, he worked for the US life science company Millipore in several management and sales-related positions. Frederic Vanderhaegen is 42 years old and a Belgian citizen.

Dr. Bernhard Grob has been appointed Head of the Partnering Business (OEM business). He has previously worked in a range of sector-specific general management and technical roles at global companies, including as Managing Director of the Analytical Instruments business unit at Mettler-Toledo. He is 54 years old and a Swiss national. Bernhard Grob will start work at Tecan on November 10, 2010 and take over his position as Head of the Partnering Business with effect from January 1, 2011, when he will also join the newly constituted Group Executive Board.

Matthew Robin, Head of Liquid Handling & Robotics since 2007 and designated Head of the new Partnering Business segment, will leave the Tecan Group and the Group Executive Board by mutual agreement with effect from December 31, 2010.

The Board of Directors and CEO of Tecan would like to thank Matthew Robin for his commitment to building the business and wish him all the best for the future.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service



2

network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

For further information:

Tecan Group

Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com